158 related articles for article (PubMed ID: 17572303)
1. Amplification of zinc finger gene 217 (ZNF217) and cancer: when good fingers go bad.
Quinlan KG; Verger A; Yaswen P; Crossley M
Biochim Biophys Acta; 2007 Jun; 1775(2):333-40. PubMed ID: 17572303
[TBL] [Abstract][Full Text] [Related]
2. Silencing of ZNF217 gene influences the biological behavior of a human ovarian cancer cell line.
Sun G; Zhou J; Yin A; Ding Y; Zhong M
Int J Oncol; 2008 May; 32(5):1065-71. PubMed ID: 18425333
[TBL] [Abstract][Full Text] [Related]
3. ZNF217 suppresses cell death associated with chemotherapy and telomere dysfunction.
Huang G; Krig S; Kowbel D; Xu H; Hyun B; Volik S; Feuerstein B; Mills GB; Stokoe D; Yaswen P; Collins C
Hum Mol Genet; 2005 Nov; 14(21):3219-25. PubMed ID: 16203743
[TBL] [Abstract][Full Text] [Related]
4. The candidate oncogene ZNF217 is frequently amplified in colon cancer.
Rooney PH; Boonsong A; McFadyen MC; McLeod HL; Cassidy J; Curran S; Murray GI
J Pathol; 2004 Nov; 204(3):282-8. PubMed ID: 15476264
[TBL] [Abstract][Full Text] [Related]
5. Specific recognition of ZNF217 and other zinc finger proteins at a surface groove of C-terminal binding proteins.
Quinlan KG; Nardini M; Verger A; Francescato P; Yaswen P; Corda D; Bolognesi M; Crossley M
Mol Cell Biol; 2006 Nov; 26(21):8159-72. PubMed ID: 16940172
[TBL] [Abstract][Full Text] [Related]
6. Chromosome 20q13.2 ZNF217 locus amplification correlates with decreased E-cadherin expression in ovarian clear cell carcinoma with PI3K-Akt pathway alterations.
Huang HN; Huang WC; Lin CH; Chiang YC; Huang HY; Kuo KT
Hum Pathol; 2014 Nov; 45(11):2318-25. PubMed ID: 25281027
[TBL] [Abstract][Full Text] [Related]
7. Prognostic and therapeutic impact of the chromosome 20q13.2 ZNF217 locus amplification in ovarian clear cell carcinoma.
Rahman MT; Nakayama K; Rahman M; Nakayama N; Ishikawa M; Katagiri A; Iida K; Nakayama S; Otsuki Y; Shih IeM; Miyazaki K
Cancer; 2012 Jun; 118(11):2846-57. PubMed ID: 22139760
[TBL] [Abstract][Full Text] [Related]
8. The ZNF217 gene amplified in breast cancers promotes immortalization of human mammary epithelial cells.
Nonet GH; Stampfer MR; Chin K; Gray JW; Collins CC; Yaswen P
Cancer Res; 2001 Feb; 61(4):1250-4. PubMed ID: 11245413
[TBL] [Abstract][Full Text] [Related]
9. [Oncogene ZNF217 amplification on chromosome 20 q in ovarian serous cystadenocarcinoma and its clinical implications].
Li J; Zhong M; Song LL; Su GD
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Jun; 26(6):824-5. PubMed ID: 16793610
[TBL] [Abstract][Full Text] [Related]
10. Positional cloning of ZNF217 and NABC1: genes amplified at 20q13.2 and overexpressed in breast carcinoma.
Collins C; Rommens JM; Kowbel D; Godfrey T; Tanner M; Hwang SI; Polikoff D; Nonet G; Cochran J; Myambo K; Jay KE; Froula J; Cloutier T; Kuo WL; Yaswen P; Dairkee S; Giovanola J; Hutchinson GB; Isola J; Kallioniemi OP; Palazzolo M; Martin C; Ericsson C; Pinkel D; Albertson D; Li WB; Gray JW
Proc Natl Acad Sci U S A; 1998 Jul; 95(15):8703-8. PubMed ID: 9671742
[TBL] [Abstract][Full Text] [Related]
11. ZNF217, a candidate breast cancer oncogene amplified at 20q13, regulates expression of the ErbB3 receptor tyrosine kinase in breast cancer cells.
Krig SR; Miller JK; Frietze S; Beckett LA; Neve RM; Farnham PJ; Yaswen PI; Sweeney CA
Oncogene; 2010 Oct; 29(40):5500-10. PubMed ID: 20661224
[TBL] [Abstract][Full Text] [Related]
12. Biochemical characterization of the zinc-finger protein 217 transcriptional repressor complex: identification of a ZNF217 consensus recognition sequence.
Cowger JJ; Zhao Q; Isovic M; Torchia J
Oncogene; 2007 May; 26(23):3378-86. PubMed ID: 17130829
[TBL] [Abstract][Full Text] [Related]
13. The transcription factor ZNF217 is a prognostic biomarker and therapeutic target during breast cancer progression.
Littlepage LE; Adler AS; Kouros-Mehr H; Huang G; Chou J; Krig SR; Griffith OL; Korkola JE; Qu K; Lawson DA; Xue Q; Sternlicht MD; Dijkgraaf GJ; Yaswen P; Rugo HS; Sweeney CA; Collins CC; Gray JW; Chang HY; Werb Z
Cancer Discov; 2012 Jul; 2(7):638-51. PubMed ID: 22728437
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive analysis of 20q13 genes in ovarian cancer identifies ADRM1 as amplification target.
Fejzo MS; Dering J; Ginther C; Anderson L; Ramos L; Walsh C; Karlan B; Slamon DJ
Genes Chromosomes Cancer; 2008 Oct; 47(10):873-83. PubMed ID: 18615678
[TBL] [Abstract][Full Text] [Related]
15. [Study on amplification of ZNF217 in primary gastric carcinoma].
Zhu YQ; Zhu ZG; Liu BY; Chen XH; Zhang Y; Yin HR
Zhonghua Wei Chang Wai Ke Za Zhi; 2005 Jan; 8(1):60-2. PubMed ID: 16149004
[TBL] [Abstract][Full Text] [Related]
16. Gene amplification of ZNF217 located at chr20q13.2 is associated with lymph node metastasis in ovarian clear cell carcinoma.
Rahman MT; Nakayama K; Rahman M; Katagiri H; Katagiri A; Ishibashi T; Ishikawa M; Iida K; Nakayama N; Otsuki Y; Nakayama S; Miyazaki K
Anticancer Res; 2012 Aug; 32(8):3091-5. PubMed ID: 22843878
[TBL] [Abstract][Full Text] [Related]
17. Detection of Her2/neu, c-MYC and ZNF217 gene amplification during breast cancer progression using fluorescence in situ hybridization.
Shimada M; Imura J; Kozaki T; Fujimori T; Asakawa S; Shimizu N; Kawaguchi R
Oncol Rep; 2005 Apr; 13(4):633-41. PubMed ID: 15756435
[TBL] [Abstract][Full Text] [Related]
18. Differentially regulated genes as putative targets of amplifications at 20q in ovarian cancers.
Watanabe T; Imoto I; Katahira T; Hirasawa A; Ishiwata I; Emi M; Takayama M; Sato A; Inazawa J
Jpn J Cancer Res; 2002 Oct; 93(10):1114-22. PubMed ID: 12417041
[TBL] [Abstract][Full Text] [Related]
19. Learning the local Bayesian network structure around the ZNF217 oncogene in breast tumours.
Prestat E; de Morais SR; Vendrell JA; Thollet A; Gautier C; Cohen PA; Aussem A
Comput Biol Med; 2013 May; 43(4):334-41. PubMed ID: 23375235
[TBL] [Abstract][Full Text] [Related]
20. The dark side of ZNF217, a key regulator of tumorigenesis with powerful biomarker value.
Cohen PA; Donini CF; Nguyen NT; Lincet H; Vendrell JA
Oncotarget; 2015 Dec; 6(39):41566-81. PubMed ID: 26431164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
